{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:45:38Z","timestamp":1761237938307},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T00:00:00Z","timestamp":1348099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["opencardiovascularmedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOCMJ"],"published-print":{"date-parts":[[2012,9,20]]},"abstract":"<jats:p>This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have mixed hyperlipidemia and rhabdomyolysis. Because of concerns with her chronic kidney disease (CKD), we temporarily stopped all her drug treatments and started insulin treatment for her type 2 diabetes (T2D). A month later when her T2D was stabilised, we prescribed atorvastatin and an omega-3 fatty acid ethyl ester supplement to treat her hypertriglyceridemia. Within two months her blood lipids were within the recommended range. In patients with stage 3\u20135 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin that is metabolised predominantly in the kidneys. To minimise adverse events without compromise on efficacy, we used a combination of omega-3 fatty acid ethyl esters, which are not metabolised in the kidneys, with a statin that is minimally metabolised in the kidneys for the treatment of her hyperlipidemia.<\/jats:p>","DOI":"10.2174\/1874192401206010122","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T04:07:53Z","timestamp":1349150873000},"page":"122-125","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters"],"prefix":"10.2174","volume":"6","author":[{"given":"Vasilios G","family":"Athyros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri P","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14656560903575654","volume":"11","author":"Athyros VG","year":"2010","unstructured":"Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy Expert Opin Pharmacother 2010; 11 : 723-30.","journal-title":"Expert Opin Pharmacother"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1185\/030079903125002315","volume":"19","author":"Athyros VG","year":"2003","unstructured":"Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP. GREACE Study Collaborative. Group. Statins and renal function in patients with diabetes mellitus Curr Med Res Opin 2003; 19 : 615-7.","journal-title":"Curr Med Res Opin"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ndt\/gfl802","volume":"22","author":"Athyros VG","year":"2007","unstructured":"Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22 : 963-4.","journal-title":"Nephrol Dial Transplant"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/j.ajkd.2005.11.031","volume":"47","author":"Liberopoulos EN","year":"2006","unstructured":"Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. The effect of cholesterol-lowering treatment on renal function Am J Kidney Dis 2006; 47 : 561-0.","journal-title":"Am J Kidney Dis"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11883-008-0079-y","volume":"10","author":"Tziomalos K","year":"2008","unstructured":"Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Omega-3 fatty acids: how can they be used in secondary prevention? Curr Atheroscler Rep 2008; 10 : 510-7.","journal-title":"Curr Atheroscler Rep"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ajcn\/63.2.234","volume":"63","author":"Schaefer EJ","year":"1996","unstructured":"Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al. Effects of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects Am J Clin Nutr 1996; 63 : 234-41.","journal-title":"Am J Clin Nutr"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ajcn\/74.3.308","volume":"74","author":"Sun Z","year":"2001","unstructured":"Sun Z, Welty FK, Dolnikowski GG, Lichtenstein AH, Schaefer EJ. Effects of a National Cholesterol Education Program Step II Diet on apolipoprotein A-IV metabolism within triacylglycerol-rich lipoproteins and plasma Am J Clin Nutr 2001; 74 : 308-14.","journal-title":"Am J Clin Nutr"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1464-5491.2008.02659.x","volume":"26","author":"Boucher BJ","year":"2009","unstructured":"Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? Diabet Med 2009; 26 : 192-3.","journal-title":"Diabet Med"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","volume":"109","author":"Bellosta S","year":"2004","unstructured":"Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 2004; 109 (III) : 50-7.","journal-title":"Circulation"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14656566.2012.661716","volume":"13","author":"Athyros VG","year":"2012","unstructured":"Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Stage of chronic kidney disease and severity of coronary heart disease manifestation Expert Opin Pharmacother 2012; 13 : 457-60.","journal-title":"Expert Opin Pharmacother"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.5114\/aoms.2011.26610","volume":"7","author":"Athyros VG","year":"2011","unstructured":"Athyros VG, Hatzitolios AI, Karagiannis A, et al. For the imperative collaborative group. improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. the imperative renal analysis Arch Med Sci 2011; 7 : 984-2.","journal-title":"Arch Med Sci"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1185\/03007995.2011.595782","volume":"27","author":"Athyros VG","year":"2011","unstructured":"Athyros VG, Karagiannis A, Ganotakis ES. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT) collaborative group. association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin 2011; 27 : 1659-68.","journal-title":"Curr Med Res Opin"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157016108783955374","volume":"6","author":"Efstratiadis G","year":"2008","unstructured":"Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6 : 93-107.","journal-title":"Curr Vasc Pharmacol"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1874192400701010008","volume":"1","author":"Athyros VG","year":"2007","unstructured":"Athyros VG, Kakafika AI, Papageorgiou AA. Statin-induced increase in HDL-C and renal function in coronary heart disease patients Open Cardiovasc Med J 2007; 1 : 8-14.","journal-title":"Open Cardiovasc Med J"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.amjcard.2012.02.038","volume":"109","author":"Athyros VG","year":"2012","unstructured":"Athyros VG, Karagiannis A, Katsiki N, Mikhailidis DP. Statins in patients with renal dysfunction Am J Cardiol 2012; 109 : 1537.","journal-title":"Am J Cardiol"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/157016112799959422","volume":"10","author":"Athyros VG","year":"2012","unstructured":"Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2012; 10 : 374-7.","journal-title":"Curr Vasc Pharmacol"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1874192400903010057","volume":"3","author":"Tziomalos K","year":"2009","unstructured":"Tziomalos K, Ganotakis ES, Gazi IF, Nair DR, Mikhailidis DP. Kidney Function and estimated vascular risk in patients with primary dyslipidemia Open Cardiovasc Med J 2009; 3 : 57-68.","journal-title":"Open Cardiovasc Med J"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/1874192401105010024","volume":"5","author":"Athyros VG","year":"2011","unstructured":"Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment Open Cardiovasc Med J 2011; 5 : 24-34.","journal-title":"Open Cardiovasc Med J"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/089686080702700224","volume":"27","author":"Athyros VG","year":"2007","unstructured":"Athyros VG, Karagiannis A, Liberopoulos EN, Elisaf M, Mikhailidis DP. Statin treatment may be beneficial to both the kidneys and the heart Perit Dial Int 2007; 27 : 215-6.","journal-title":"Perit Dial Int"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874192401206010028","volume":"6","author":"Mitsiou EK","year":"2012","unstructured":"Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DP. Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J 2012; 6 : 28-32.","journal-title":"Open Cardiovasc Med J"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/1874192401105010220","volume":"5","author":"Fabbian F","year":"2011","unstructured":"Fabbian F, Pala M, Giorgi A De, et al. Clinical features of cardiorenal syndrome in a cohort of consecutive patients admitted to an internal medicine ward Open Cardiovasc Med J 2011; 5 : 220-5.","journal-title":"Open Cardiovasc Med J"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/1874192401105010226","volume":"5","author":"Athyros VG","year":"2011","unstructured":"Athyros VG, Katsiki N, Tziomalos K, Karagiannis A. Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011; 5 : 226-30.","journal-title":"Open Cardiovasc Med J"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Reiner","year":"2011","unstructured":"Reiner , Catapano AL, De Backer G, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 2011; 32 : 1769-818.","journal-title":"Eur Heart J"},{"key":"refR24","first-page":"S13","volume":"49","year":"2007","unstructured":"Diabetes and Chronic Kidney Disease Work Group. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 2007; 49 : S13-9.","journal-title":"Am J Kidney Dis"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","volume":"57","author":"Athyros VG","year":"2004","unstructured":"Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease.A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study J Clin Pathol 2004; 57 : 728-34.","journal-title":"J Clin Pathol"},{"key":"refR26","first-page":"CD007784","author":"Navaneethan SD","year":"2009","unstructured":"Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev 2009; CD007784.","journal-title":"Cochrane Database Syst Rev"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2362.2002.01001.x","volume":"32","author":"Chan DC","year":"2002","unstructured":"Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity Eur J Clin Invest 2002; 32 : 429-36.","journal-title":"Eur J Clin Invest"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/heart.85.5.544","volume":"85","author":"Durrington PN","year":"2001","unstructured":"Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia Heart 2001; 85 : 544-8.","journal-title":"Heart"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2337\/diabetes.51.8.2377","volume":"51","author":"Chan DC","year":"2002","unstructured":"Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 2002; 51 : 2377-86.","journal-title":"Diabetes"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","volume":"29","author":"Davidson MH","year":"2007","unstructured":"Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 2007; 29 : 1354-67.","journal-title":"Clin Ther"}],"container-title":["The Open Cardiovascular Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V6\/TOCMJ-6-122\/TOCMJ-6-122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V6\/TOCMJ-6-122\/TOCMJ-6-122.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V6\/TOCMJ-6-122\/TOCMJ-6-122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:11:11Z","timestamp":1594725071000},"score":1,"resource":{"primary":{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/VOLUME\/6\/PAGE\/122\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,9,20]]}},"alternative-id":["TOCMJ-6-122"],"URL":"https:\/\/doi.org\/10.2174\/1874192401206010122","relation":{},"ISSN":["1874-1924"],"issn-type":[{"value":"1874-1924","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2012-8-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-9-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-9-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}